Merck and Moderna reported median five-year follow-up data from their Phase 2b KEYNOTE-942 study of intismeran autogene combined with Keytruda in high-risk stage III/IV melanoma. The combination therapy delivered a 49% reduction in the risk of recurrence or death versus Keytruda alone, matching the benefit observed at the three-year analysis. Safety findings remained consistent with earlier reports, and the companies plan to present full primary and secondary endpoint data at an upcoming oncology conference. With roughly 112,000 new U.S. melanoma cases projected for 2026, analysts at Jefferies estimate peak annual sales in melanoma could reach several billion dollars if pricing aligns near Keytruda’s $200,000 level. Multiple Phase 3 trials in melanoma, non-small cell lung cancer, renal cell carcinoma and bladder cancer are underway to expand the platform’s potential.

Merck has joined forces with the Coalition for Epidemic Preparedness Innovations on a $30 million program to develop an updated version of its Ebola vaccine designed for low- and middle-income countries. The initiative will support process improvements to lower manufacturing costs, scale production capacity and strengthen distribution channels in sub-Saharan Africa. CEPI will contribute expertise in regulatory strategy and access planning, while Merck will leverage its established viral vector platform. Stakeholders anticipate that the program could reduce per-dose manufacturing costs by up to 40%, significantly improving outbreak response readiness in vulnerable regions.

Merck faces growing headwinds as Gardasil continues to experience sharp sales declines in China and Japan, putting pressure on its upcoming fourth-quarter earnings. In China, quarterly vaccine shipments fell more than 25% year-over-year, while Japan recorded a 30% decline amid increased competition and regulatory delays. Analysts expect Merck’s vaccine division growth to decelerate to the low single digits in Q4, compared with mid-teens growth in the prior year period. Investor focus will center on management’s strategy to revitalize Gardasil uptake through new pricing agreements, expanded age indications and targeted vaccination campaigns in key emerging markets.